Welcome to Lab Test Consult

You can log in and post your comments

Share your knowledge and experience!

Member Login
Lost your password?

NovoLog (Type 2 Diabetes)

December 29, 2011
By

NEW YORK , Dec. 28, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

NovoLog (Type 2 Diabetes) – Analysis and Forecasts to 2020

http://www.reportlinker.com/p0657168/NovoLog-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswireutm_medium=prutm_campaign=Pathology

NovoLog (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “NovoLog (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides NovoLog sales estimates for US, EU5 and Japan . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData’s team of industry experts.

Scope

– Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

– Analysis and review of NovoLog including sales data

– Qualitative and quantitative assessment of market space

– Analysis of the trends, drivers and restraints shaping and defining the markets

– In-depth analysis ofNovoLog including efficacy, safety, pricing and other details which influence its sales potential

– Detailed sales forecast for 2011-2020 for NovoLog in the US, EU5 and Japan

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of competition by understanding the changing competitive landscape

– Effectively plan your MA and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of the drug’s performance

– Examine the historical sales performance of a drug in seven major markets

– Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 5

2.1 Diabetes 5

2.2 Epidemiology 5

2.2.1 Prevalence 5

2.2.2 Mortality 7

2.3 Etiology and Risk Factors 9

2.3.1 Obesity 9

2.3.2 Sedentary Lifestyle 9

2.3.3 Family History and Genetics 9

2.3.4 Ethnicity 9

2.3.5 Old Age 9

2.4 Economic Impact of Diabetes 9

2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

3.1 Type 2 Diabetes Market 12

3.2 Type 2 Diabetes Market Forecasts 13

3.3 Type 2 Diabetes Market: Drivers and Restraints 14

3.3.1 Drivers 14

3.3.2 Restraints 15

4 Classification of Diabetes 16

4.1 Types of Diabetes 16

4.1.1 Type 1 Diabetes 16

4.1.2 Type 2 Diabetes 16

4.1.3 Gestational Diabetes 16

4.2 Diabetes Complications 16

4.2.1 Cardiovascular Disease 16

4.2.2 Nephropathy 17

4.2.3 Neuropathy 17

4.2.4 Amputation 17

4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19

6.2 Oral Medications 19

6.2.1 Sulfonylureas (SUR) 19

6.2.2 Biguanides (BGDs) 19

6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21

6.2.4 Meglitinides 21

6.2.5 Thiazolidinediones (TZDs) 22

6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23

6.2.7 Oral Combination Therapy 23

6.3 Other Injectionable Medications 24

6.3.1 Pramlintide 24

6.3.2 Exenatide 24

6.4 Market Share as per Classes in Type 2 Diabetes 24

7 NovoLog (insulin aspart) 25

7.1 Introduction 25

7.2 Mechanism of Action 25

7.3 Clinical Studies 25

7.3.1 Subcutaneous NovoLog Administration in Type 2 Diabetes 25

7.3.2 Pump Therapy in Type 2 Diabetes 25

7.4 Approval History of NovoLog 26

7.5 Factors Affecting Sales 26

7.5.1 Growing Insulin Market 26

7.5.2 Advantage of NovoLog over Regular Human Insulin and Other Insulin Analogs 26

7.5.3 Prevention of Spiking Blood Sugar between Meals 27

7.5.4 Effective treatment for Low blood sugar at night 27

7.5.5 Very Low Competition at Launch Year 27

7.6 Drug Evaluation 27

7.6.1 Drug Risk Benefit Score 27

7.6.2 Intensity of Competition 28

7.7 Sales Estimates 28

7.7.1 Target Patient Pool for NovoLog 28

7.7.2 Dosing 29

7.7.3 Market Penetration 29

7.7.4 Annual Cost of Therapy 29

7.7.5 Sales Projections of NovoLog 30

8 Diabetes Market: Appendix 39

8.1 Market Definitions 39

8.2 List of Abberiviations 39

8.3 Research Methodology 39

8.3.1 Coverage 39

8.3.2 Secondary Research 40

8.3.3 Forecasting 40

8.3.4 Number of patients approved to take the drug 40

8.3.5 Net Penetration of Drug 41

8.3.6 Net Annual Dosing 41

8.3.7 Annual Cost of Therapy 41

8.4 Drug Sales Estimates Model 41

8.5 Contact Us 41

8.6 Disclaimer 41

9 Sources 42

List of Tables

Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5

Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7

Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10

Table 4: Type 2 Diabetes, World, Major Marketed Drugs by Sales ($m), 2010 12

Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trials 13

Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14

Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15

Table 8: Diabetes Drugs Evolution 18

Table 9: Subcutaneous Administration of NovoLog for Type 2 Diabetes 25

Table 10: Pump Therapy in Type 2 Diabetes 26

Table 11: Approval History of NovoLog 26

Table 12: Drug Risk Benefit Score of NovoLog 27

Table 13: NovoLog, Annual Cost of Therapy in Type 2 Diabetes, Global, 2011 29

Table 14: NovoLog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002–2020 30

Table 15: NovoLog, Type 2 Diabetes, the US, Sales Estimates ($m), 2002–2020 31

Table 16: NovoLog, Type 2 Diabetes, the UK, Sales Estimates ($m), 2002–2020 32

Table 17: NovoLog, Type 2 Diabetes, France , Sales Estimates ($m), 2002–2020 33

Table 18: NovoLog, Type 2 Diabetes, Germany , Sales Estimates ($m), 2002–2020 34

Table 19: NovoLog, Type 2 Diabetes, Italy , Sales Estimates ($m), 2002–2020 35

Table 20: NovoLog, Type 2 Diabetes, Spain , Sales Estimates ($m), 2002–2020 36

Table 21: NovoLog, Type 2 Diabetes, Japan , Sales Estimates ($m), 2002–2020 37

List of Figures

Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6

Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6

Figure 3: Diabetes, World, Mortality, 2010 7

Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8

Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 13

Figure 6: Mechanism of Action of Sulfonylureas 19

Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20

Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21

Figure 9: Mechanism of Action of Thiazolidinediones 22

Figure 10: Mechanism of Action of DPP IV Inhibitors 23

Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 24

Figure 12: NovoLog, Type 2 Diabetes, Global, Sales Estimates ($m), 2002-2010 30

Figure 13: NovoLog, Type 2 Diabetes, the US, Sales Estimates ($m), 2002–2020 31

Figure 14: NovoLog, Type 2 Diabetes, the UK, Sales Estimates ($m), 2002–2020 32

Figure 15: NovoLog, Type 2 Diabetes, France , Sales Estimates ($m), 2002–2020 33

Figure 16: NovoLog, Type 2 Diabetes, Germany , Sales Estimates ($m), 2002–2020 34

Figure 17: NovoLog, Type 2 Diabetes, Italy , Sales Estimates ($m), 2002–2020 35

Figure 18: NovoLog, Type 2 Diabetes, Spain , Sales Estimates ($m), 2002–2020 36

Figure 19: NovoLog, Type 2 Diabetes, Japan , Sales Estimates ($m), 2002-2020 37

Figure 20: NovoLog, Diabetes, Global, Sales Distribution (%), 2020 38

Figure 21: Patients Approved for the Drug 40

To order this report:

Pathology Industry: NovoLog (Type 2 Diabetes) – Analysis and Forecasts to 2020

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Article source: http://finance.yahoo.com/news/novolog-type-2-diabetes-analysis-104600169.html

Share

Related posts:

  1. Teva Invests in Potential Type 1 Diabetes Therapy Once Rejected by Sanofi
  2. Diabetes just my type
  3. Intensive Control of Type 1 Diabetes Helps Kidneys: Study
  4. Diabetes Type 1 As It Unfolds
  5. Research and Markets: Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H2, 2011
  6. Depression increases risk of dementia in patients with Type 2 diabetes
  7. China’s Thirst for New Diabetes Drugs Threatens Bayer’s Lead
  8. Diabetes Will Strike One in Ten Adults by 2030, IDF Report Says
  9. American Diabetes Association and Walgreens Collaborating to Help Stop Diabetes(R)
  10. India’s diabetes burden to cross 100 million by 2030

Tags:



New post

Posts

October 2017
M T W T F S S
« Aug    
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Posts

Recent comments

    Contact Sign In

    Email Marketing You Can Trust